comparemela.com
Home
Live Updates
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism : comparemela.com
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today
Related Keywords
Stephanie Carrington
,
Nevan Charles Elam
,
Rezolute Inc
,
Nasdaq
,
Securities Exchange
,
European Medicines Agency
,
Chief Executive Officer
,
Securities Act
,
Securities Exchange Act
,
Private Securities Litigation Reform Act
,
Risk Factors
,
Annual Report
,
Quarterly Reports
,
Region
,
comparemela.com © 2020. All Rights Reserved.